• 1
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Association, 2000.
  • 2
    Hodgins DC, Stea JN, Grant JE. Gambling disorders. Lancet 2011; 378: 18741884.
  • 3
    Gerstein D, Murphy S, Toce M, Hoffman J, Palmer A, Johnson R, Larison C, Chuchro L, Buie T, Engelman L, Hill MA, Volberg R, Harwood H, Tucker A, Christiansen E, Cummings W, Sinclair S. Gambling Impact and Behavior Study: Final Report to the National Gambling Impact Study Commission. Chicago, IL: National Opinion Research Center (NORC), 1999.
  • 4
    Grant JE, Kim SW. Demographic and clinical characteristics of 131 adult pathological gamblers. J Clin Psychiatry 2001; 62: 957962.
  • 5
    Morasco BJ, Petry NM. Gambling problems and health functioning in individuals receiving disability. Disabil Rehabil 2006; 28: 619623.
  • 6
    Hong SI, Sacco P, Cunningham-Williams RM. An empirical typology of lifetime and current gambling behaviors: association with health status of older adults. Aging Ment Health 2009; 13: 265273.
  • 7
    Chou KL, Afifi TO. Disordered (pathologic or problem) gambling and axis I psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Am J Epidemiol 2011; 173: 12891297.
  • 8
    Grant JE, Kim SW. Quality of life in kleptomania and pathological gambling. Compr Psychiatry 2005; 46: 3437.
  • 9
    Black DW, Moyer T, Schlosser S. Quality of life and family history in pathological gambling. J Nerv Ment Dis 2003; 191: 124126.
  • 10
    Ledgerwood DM, Petry NM. Gambling and suicidality in treatment-seeking pathological gamblers. J Nerv Ment Dis 2004; 192: 711714.
  • 11
    Van den Brink W. Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Curr Drug Abuse Rev 2012; 5: 331.
  • 12
    Achab S, Khazaal Y. Psychopharmacological treatment in pathological gambling: a critical review. Curr Pharm Des 2011; 17: 13891395.
  • 13
    Hollander E , ed. Obsessive-Compulsive Related Disorders. Washington DC: American Psychiatric Press, Inc., 1993.
  • 14
    Moreno I, Saiz-Ruiz J, Lopez-Ibor JJ. Serotonin and gambling dependence. Hum Psychopharmacol 1991; 6: S912.
  • 15
    Carrasco JL, Saiz Ruiz J, Moreno I, Hollander E, Lopez-Ibor JJ. Low platelet MAO activity in pathological gambling. Acta Psychiatr Scand 1994; 90: 427431.
  • 16
    Decaria CM, Hollander EH, Grossman R, Wong CM, Mosovich SA, Cherkasky S. Diagnosis, neurobiology, and treatment of pathological gambling. J Clin Psychiatry 1996; 57: 8084.
  • 17
    Hollander D, Frenkel M, Decaria C, Trungold S, Stein DJ. Treatment of pathological gambling with clomipramine. Am J Psychiatry 1992; 149: 710711.
  • 18
    Black DW, Mohnahn P, Gabel J. Fluvoxamine in the treatment of compulsive buying. J Clin Psychiatry 1997; 58: 159163.
  • 19
    Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49: 914921.
  • 20
    Kim SW. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry 1998; 59: 159164.
  • 21
    Dannon PN, Lowngrub K, Gonopolski Y, Musin E, Kolter M. Pathological gambling: a review of phenomenological models and treatment modalities for an underrecognized psychiatric disorder. Primary Care Companion. J Clin Psychiatry 2006; 8: 334339.
  • 22
    Blanco C, Moreyra P, Nunes EV, Sáiz-Ruiz J, Ibáñez A. Pathological gambling: addiction or compulsion? Semin Clin Neuropsychiatry 2001; 6: 167176.
  • 23
    Dell'Osso B, Allen A, Hollander E. Comorbidity issues in the pharmacological treatment of pathological gambling: a criticial review. Clin Pract Epidemol Ment Health 2005; 1: 21.
  • 24
    Shah KR, Eisen SA, Xian H, Potenza MN. Genetic studies of pathological gambling: a review of methodology and analysis of data from the Vietnam Era Twin Registry. J Gambl Stud 2005; 21: 179203.
  • 25
    Black DW, Monahan PO, Temkit M, Shaw M. A family study of pathological gambling. Psychiatry Res 2006; 141: 295303.
  • 26
    Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 2002; 63: 501507.
  • 27
    Grant JE, Kim SW, Potenza MN, Blanco C, Ibáñez A, Stevens L, Hektner JM, Zaninelli R. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol 2003; 18: 243249.
  • 28
    Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000; 47: 813817.
  • 29
    Blanco C, Petkova E, Ibáñez A, Sáiz-Ruiz J. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 2002; 14: 915.
  • 30
    Chung SK, You IH, Cho GH, Chung GH, Shin YC, Kim DJ, Choi SW. Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J 2009; 50: 441444.
  • 31
    Sáiz-Ruiz J, Blanco C, Ibáñez A, Masramon X, Gómez MM, Madrigal M, Díez T. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry 2005; 66: 2833.
  • 32
    Black DW, Arndt S, Coryell WH, Argo T, Forbush KT, Shaw MC, Perry P, Allen J. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacol 2007; 27: 143150.
  • 33
    Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of pathological gambling urges. J Clin Psychiatry 2008; 69: 783789.
  • 34
    Toneatto T, Brands B, Selby P. A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict 2009; 18: 219225.
  • 35
    Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163: 303312.
  • 36
    Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry 2010; 197: 330331.
  • 37
    Dannon PN, Lowengrub K, Musin E, Gonopolsky Y, Kotler M. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J Clin Psychopharmacol 2007; 27: 620624.
  • 38
    Grant JE, Kim SW, Hollander E, Potenza MN. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl) 2008; 200: 521527.
  • 39
    Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 2005; 162: 137145.
  • 40
    Hollander E, Buchsbaum MS, Haznedar MM, Berenguer J, Berlin HA, Chaplin W, Goodman CR, LiCalzi EM, Newmark R, Pallanti S. FDG-PET study in pathological gamblers. Lithium increases orbitofrontal, dorsolateral and cingulate metabolism. Neuropsychobiology 2008; 58: 3747.
  • 41
    Dannon PN, Lowengrub K, Gonopolski Y, Musin E, Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005; 28: 610.
  • 42
    Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T, Pallanti S, Hollander E. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry 2011 Epub April 12; doi:10.3109/15622975.2011.560964.
  • 43
    McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry 2008; 69: e18.
  • 44
    Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav 2008; 89: 298303.
  • 45
    Kalivas PW, Peters J, Knackstedt L. Animal models and brain circuits in drug addiction. Mol Interv 2006; 6: 339344.
  • 46
    Gray KM, Watson NL, Carpenter MJ, Larowe SD. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict 2010; 19: 187189.
  • 47
    Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van den Brink W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res 2011; 17: 211216.
  • 48
    Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62: 652657.
  • 49
    Zack M, Poulos CX. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology 2004; 29: 195207.
  • 50
    Chamberlain SR, Grant JE, Costa A, Müller U, Sahakian BJ. Effects of acute modafinil on cognition in trichotillomania. Psychopharmacology (Berl) 2010; 212: 597601.
  • 51
    Grant JE, Chamberlain SR, Odlaug BL, Potenza MN, Kim SW. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl) 2010; 212: 603612.